![]() is accredited by URAC, for Health Content Provider (URAC's accreditation program is an independent audit to verify that A.D.A.M. Taking blood thinner drugs to treat or prevent blood clots.Ī.D.A.M., Inc.Taking vitamin D supplements if nephrotic syndrome is long-term and is not responding to treatment.Your provider may suggest a moderate-protein diet (1 gram of protein per kilogram of body weight per day). Water pills (diuretics) may also help with this problem. A low-sodium diet may help with swelling in the hands and legs.Medicines to reduce cholesterol and triglycerides (usually statins) may be needed. Treating high cholesterol to reduce the risk for heart and blood vessel problems - A low-fat, low-cholesterol diet is usually not enough for people with nephrotic syndrome.Corticosteroids and other drugs that suppress or quiet the immune system.ACE inhibitors and ARBs may also help decrease the amount of protein lost in the urine. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are the medicines most often used. Keeping blood pressure at or below 130/80 mm Hg to delay kidney damage.Treatments may include any of the following: To control nephrotic syndrome, the disorder that is causing it must be treated. These results suggest that subjects with SCH are susceptible to increased platelet activation and increased MPV values which contribute to increased risk of cardiovascular complications.The goals of treatment are to relieve symptoms, prevent complications, and delay kidney damage. However, post-treatment MPV values were still higher (p=0.035) in the patient group than in control group. MPV values were decreased after subclinical hypothyroidic patients became eythyroid. MPV was found to be correlated with only antithyroid peroxidase (anti-TPO) antibody levels (P<0.001). Serum triglyceride and MPV values were significantly higher (pTG=0.007 and pMPV<0.001) while HDLC levels were lower (pHDLC=0.008) in the subclinical hypothyroidic group. Platelet counts and metabolic parameters, except serum triglyceride and high density lipoprotein cholesterol (HDLC) levels, were similar between the two groups. Subclinical hypothyroidic patients were then reevaluated with the same parameters when they became euthyroid after 12 weeks of levothyroxine treatment. All the study subjects were evaluated by biochemical and platelet parameters. None of the study subject had diabetes, hypertension or dyslipidemia. Sixty patients with subclinical hypothyroidism and 78 euthyroid healthy subjects matched for age, gender and body mass index were enrolled in the study. The aim of this study was to evaluate MPV values in subclinical hypothyroidic patients when they were subclinical hypothyroidic and became euthyroidic after 12 weeks of levothyroxine replacement therapy. On the other hand, mean platelet volume (MPV), which is a determinant of platelet function, is an independent risk factor for cardiovascular disease. It has been suggested as a risk factor for cardiovascular disease. Since it is generally asymptomatic, these patients are mostly identified through routine screening or evaluation of non-specific symptoms. Subclinical hypothyroidism (SCH) is frequently encountered in the general population.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |